Ignite Creation Date:
2025-12-24 @ 5:29 PM
Ignite Modification Date:
2026-02-20 @ 4:49 PM
Study NCT ID:
NCT03892668
Status:
COMPLETED
Last Update Posted:
2020-04-28
First Post:
2019-03-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy.
Sponsor:
Cairo University
Organization:
Study Overview
Official Title:
Safety and Efficacy of Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy; A Randomized Controlled Trial
Status:
COMPLETED
Status Verified Date:
2020-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Uterine leiomyomas (fibroids) are the most common benign tumors among women. Fibroids are found in approximately 20% of women over 35 years of age. In 20-50% of patients, fibroids may cause problems such as heavy menstrual bleeding, anemia, pelvic pain, pressure symptoms from extrinsic compression of the colorectal and urinary tract. Surgery is indicated for symptomatic uterine leiomyomas; hysterectomy for women who have completed childbearing (women \> 40 years old), and myomectomy for women \<40 years old who wish to preserve uterus and fertility.
Detailed Description:
Interventions:
Preoperative
* Full history, where demographic characteristics will be reported and examination to detect the size and mobility of uterus.
* Informed consent will be taken from patients.
* Trans-vaginal U/S to assess number, size, and types of myomas.
* Preoperative full labs (Hemoglobin, hematocrit, INR, liver enzymes and kidney functions)
Intra Operative
* Preoperative antibiotics will be given before the beginning of the operation. The operations will be performed as standard through a midline or Pfannenstiel incision by the same consultant gynecologist to ensure consistency of study procedures. All patients will receive general anesthesia. After the skin incision, the subcutaneous fat and abdominal fascia will be opened crosswise, and the rectus muscle will be opened on the midline. The parietal peritoneum will be opened longitudinally to reach the pelvic cavity. Subsequently, a self-retaining retractor will be inserted, and intestine will be packed. The uterus will be inspected for the number, location, and shape of myomas. Other pelvic organs will be inspected for any associated pathology. When possible, uterine incisions will be performed on the anterior wall or fundus in order to reduce postoperative adhesions. The incision will be performed using monopolar diathermy. Intracapsular enucleation of myomas will be performed by gently dissecting between the myoma and the pseudo-capsule. The myoma will be gently enucleated out. Meticulous hemostasis will be secured by low-voltage coagulation of feeding vessels. Myoma bed will be closed by 1 or 2 layers of interrupted vicryl sutures (Vicryl 1-0 polyglactin 910; Egycryl, Taisier CO, Egypt). No mechanical tourniquet or local vasoocclusive drugs (e.g., vasopressin) will be used intraoperatively.
* The study will include patients scheduled for open abdominal myomectomy and will be divided into three equal groups.
* All the three groups will take a standard dose of 400 microgram of misoprostol rectally one hour before the operation.
Postoperative
* Estimation of Hemoglobin 6 hrs postoperatively and next day morning.
* Monitor Vital Signs and need for blood transfusion.
* Send myomas for pathology.
Preoperative
* Full history, where demographic characteristics will be reported and examination to detect the size and mobility of uterus.
* Informed consent will be taken from patients.
* Trans-vaginal U/S to assess number, size, and types of myomas.
* Preoperative full labs (Hemoglobin, hematocrit, INR, liver enzymes and kidney functions)
Intra Operative
* Preoperative antibiotics will be given before the beginning of the operation. The operations will be performed as standard through a midline or Pfannenstiel incision by the same consultant gynecologist to ensure consistency of study procedures. All patients will receive general anesthesia. After the skin incision, the subcutaneous fat and abdominal fascia will be opened crosswise, and the rectus muscle will be opened on the midline. The parietal peritoneum will be opened longitudinally to reach the pelvic cavity. Subsequently, a self-retaining retractor will be inserted, and intestine will be packed. The uterus will be inspected for the number, location, and shape of myomas. Other pelvic organs will be inspected for any associated pathology. When possible, uterine incisions will be performed on the anterior wall or fundus in order to reduce postoperative adhesions. The incision will be performed using monopolar diathermy. Intracapsular enucleation of myomas will be performed by gently dissecting between the myoma and the pseudo-capsule. The myoma will be gently enucleated out. Meticulous hemostasis will be secured by low-voltage coagulation of feeding vessels. Myoma bed will be closed by 1 or 2 layers of interrupted vicryl sutures (Vicryl 1-0 polyglactin 910; Egycryl, Taisier CO, Egypt). No mechanical tourniquet or local vasoocclusive drugs (e.g., vasopressin) will be used intraoperatively.
* The study will include patients scheduled for open abdominal myomectomy and will be divided into three equal groups.
* All the three groups will take a standard dose of 400 microgram of misoprostol rectally one hour before the operation.
Postoperative
* Estimation of Hemoglobin 6 hrs postoperatively and next day morning.
* Monitor Vital Signs and need for blood transfusion.
* Send myomas for pathology.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: